Advertisement
Advertisement
XERS
Xeris Biopharma Holdings, Inc. Common Stock
16.97
USDSponsored
+0.35
+2.11%
Nov 20, 15:59 UTC -5
Closed
After-Market
16.97
0.00
-0.01%
Xeris Biopharma Holdings, Inc. Common Stock (XERS) Earnings
XERS Earnings Reports
Positive Surprise Ratio
XERS beat 19 of 34 last estimates.
56%
Next Report
Date of Next Report
Mar 01, 2027
Estimate for Q4 26 (Revenue/ EPS)
$120.99M
/$0.04
Implied change from Q3 26 (Revenue/ EPS)
+12.84%
/-33.33%
Implied change from Q4 25 (Revenue/ EPS)
+41.00%
/-33.33%
Xeris Biopharma Holdings, Inc. Common Stock earnings per share and revenue
On Nov 05, 2026, XERS reported earnings of 0.06 USD per share (EPS) for Q3 26, beating the estimate of 0.02 USD, resulting in a 144.90% surprise. Revenue reached 107.22 million, compared to an expected 103.55 million, with a 3.55% difference. The market reacted with a +25.05% price change (close before vs. close after earnings).
Looking ahead to Q4 26, -- analysts forecast an EPS of 0.04 USD, with revenue projected to reach 120.99 million USD, implying an decrease of -33.33% EPS, and increase of 12.84% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Apnimed, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.62
Actual
-$0.99
Surprise
-59.11%

Larimar Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.35
Actual
-$0.28
Surprise
+17.38%

Lexeo Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.33
Actual
-$0.43
Surprise
-28.17%

Galectin Therapeutics Inc.
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.04
Surprise
+21.57%

NRX Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.21
Actual
-$0.05
Surprise
+76.94%

Unicycive Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.32
Actual
-$0.25
Surprise
+21.88%

Actinium Pharmaceuticals, Inc
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.19
Surprise
+23.45%

Marker Therapeutics, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.11
Actual
-$0.10
Surprise
+15.97%

Scienture Holdings, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$1.60
Actual
-$3.76
Surprise
-134.79%

60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
Nov 16, 2026 For Q3 26
Estimate
-$0.74
Actual
-$0.75
Surprise
-0.73%
FAQ
What were Xeris Biopharma Holdings, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Xeris Biopharma Holdings, Inc. Common Stock reported EPS of $0.06, beating estimates by 144.9%, and revenue of $107.22M, 3.55% above expectations.
How did the market react to Xeris Biopharma Holdings, Inc. Common Stock's Q3 2026 earnings?
The stock price moved up 25.05%, changed from $10.46 before the earnings release to $13.08 the day after.
When is Xeris Biopharma Holdings, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 01, 2027.
What are the forecasts for Xeris Biopharma Holdings, Inc. Common Stock's next earnings report?
Based on --
analysts, Xeris Biopharma Holdings, Inc. Common Stock is expected to report EPS of $0.04 and revenue of $120.99M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.